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Abstract
Introduction: It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI).
However, the validity of this hypothesis remains unclear.
Methods: A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of
hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials
were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence
intervals (CI) were computed under a random effects model.
Results: Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin
and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis.
Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; P < 0.0001), while hyperoncotic
HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; P = 0.0008). Parallel effects on mortality were observed,
with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; P = 0.035) and hyperoncotic
HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; P = 0.043).
Conclusions: This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure
the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES
showing nephrotoxicity.
Introduction
The potential for beneficial or deleterious renal effects
is a key consideration in the selection and use of colloid
solutions for clinical fluid management. In a systematic
review, albumin was found to protect the kidney,
whereas the carbohydrate-based artificial colloids hydro-
xyethyl starch (HES) and dextran were frequently asso-
ciated with acute kidney injury (AKI) [1]. Confirmation
with respect to the negative effects of HES has been
provided by two recent meta-analyses of randomized
trials showing increased incidence of acute renal failure
(ARF) [2] and need for renal replacement therapy
(RRT) [3] in patients receiving HES and by a systematic
review [4].
Renal effects might be influenced not only by the spe-
cific properties of the particular colloid molecule but
also by higher colloid osmotic pressure (COP) [5],
assuming that increased COP decreases effective
glomerular filtration pressure and thus glomerular filtra-
tion rate antagonizing hydrostatic pressure [6]. Colloid
solutions can be classified as hypo-oncotic, iso-oncotic,
or hyperoncotic according to whether their COP is less
than, similar to, or greater than that of plasma, respec-
tively. COP is strongly dependent upon the concentra-
tion of colloid in the solution [7]. Thus, 4% to 5%
albumin is hypo-oncotic, whereas 20% to 25% albumin
is hyperoncotic [8-11]. Similarly, 6% HES is iso-oncotic,
whereas 10% HES is hyperoncotic [8,9,11,12]. Molecular
weight and substitution show little if any effect on the
COP of HES solutions [9,11].
With their capacity to draw interstitial fluid into the
intravascular compartment, hyperoncotic solutions pro-
vide an attractive option for volume expansion because
they are rapidly effective in a small infused volume and
can serve to minimize edema [13]. However, in an ana-
lysis of data from the CRYstalloids or COlloids
(CRYCO) study observational study of 1,013 intensive
care unit patients, exposure to hyperoncotic solutions of
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occurrence of AKI as compared with crystalloids or
hypo-oncotic colloids [5]. That analysis suggests that
hyperoncotic colloids per se might be harmful to the
kidney. On the other hand, no adverse renal effects
were evident in a multicenter study of 600 patients
receiving hyperoncotic 25% albumin [14] or in a recent
meta-analysis of 25 randomized trials (with a total of
1,485 patients) evaluating hyperoncotic albumin [13].
Moreover, in randomized trials, iso-oncotic 6% HES
increased the incidence of ARF in patients with severe
sepsis or septic shock [15] and the need for RRT after
kidney transplantation [16]. In light of the conflicting
data, investigators are uncertain about the renal effects
of hyperoncotic colloids. The present meta-analysis of
randomized trials was designed to test the hypothesis
that hyperoncotic colloids per se increase the incidence
of AKI.
Materials and methods
Endpoints
This meta-analysis addressed the question: does infusion
of hyperoncotic 20% to 25% albumin or 10% HES to
prevent or correct hypovolemia increase the risk of AKI
as compared with crystalloid, hypo-oncotic 4% to 5%
albumin, or no fluid? Mortality was a secondary
endpoint.
Study selection
Parallel-group randomized controlled trials (RCTs) were
eligible for inclusion if they evaluated the occurrence of
AKI in patients receiving hyperoncotic solutions of 20%
to 25% albumin or 10% HES for prevention or correc-
tion of hypovolemia. The control regimen could consist
of crystalloid, hypo-oncotic 4% to 5% albumin, or no
f l u i db u tn o tan o n - f l u i di n t e r v e n t i o ns u c ha sa na c t i v e
drug or a procedure. Hypo-oncotic colloids were also
included as control fluids in the CRYCO study [5].
Trials employing an iso-oncotic 6% HES control arm or
comparing two hyperoncotic colloids were excluded.
T h ed i f f e r e n c ei nc o l l o i do s m o t i cp r e s s u r e( C O P )
between hyperoncotic colloids and iso-oncotic 6% HES
of 12 to 18 mm Hg is smaller than that between hyper-
oncotic colloids and hypo-oncotic 4% to 5% albumin
[8,9]; as a consequence of the smaller difference, AKI
and mortality comparisons versus iso-oncotic 6% HES
as a control fluid would likely be relatively insensitive.
Colloids were classified as hyperoncotic on the basis of
final concentration at the time of use; hence, cardiac
surgery trials of extracorporeal circuit priming in which
hyperoncotic colloid was extensively diluted prior to use
were not eligible. No restrictions were placed on trial
time period or reporting language. Both published and
unpublished trials were sought.
Search strategy
Computer searches were performed between April and
July 2010 in Medline, Embase, records of published and
unpublished trials in the Cochrane Library, the Clinical-
Trials.gov website, and the abstract databases from major
meetings in surgery, anesthesiology, intensive care, and
hepatology. The search terms of inclusion were the follow-
ing: kidney, renal, renin, mortality, injury, failure, compli-
cation, adverse, illness, outcome, cirrhosis, albumin,
hetastarch, pentastarch, pentaspan, hyperoncotic, 10%,
20%, 25%, clinical trials, prospective studies, fluid therapy,
random allocation, and humans. The search terms of
exclusion were cohort study, observational, survey, phar-
macokinetic, retrospective studies, RCTs as topic, practice
guidelines as topic, animal, rats, pigs, swine, review, news,
letter, comment, editorial, meta-analysis, hypervolemia,
molecular adsorbent recirculating system [MARS], MARS,
albumin-bound, chemotherapy, paclitaxel, methotrexate,
nanoparticle, and microsphere. Roots and variants of the
search terms were also used. Eligible trials were also
sought by examining the reference lists of primary study
publications and review articles and contacting resuscita-
tion fluid suppliers. All investigators participated in deter-
mining the eligibility of candidate trials. Differences in
interpretation were resolved through discussion.
Data extraction
The authors, time periods, patients, and methods of
each trial report were scrutinized to avoid duplication
and ensure the most complete possible data set. From
the reports of the included studies, the following data
were extracted: year reported, number of patients, clini-
cal indication, blinding, allocation concealment, patient
age and gender, fluid regimen, criteria for diagnosing
AKI, and incidence of AKI and death on the basis of
intent to treat.
Statistical analysis
The pooled odds ratios (ORs) for AKI and mortality and
their 95% confidence intervals (CIs) were computed
under a random effects model. Heterogeneity was evalu-
ated by Cochran Q test and calculation of the I
2 statistic
and publication bias by linear regression of standardized
effect in relation to precision. Study quality was judged
on the basis of blinding and allocation concealment.
Analysis was performed with Comprehensive Meta Ana-
lysis version 2.2.048 (Biostat, Inc., Englewood, NJ, USA)
statistical software.
Results
Included trials
The number of candidate RCTs identified and screened
was 109 (Figure 1). Upon detailed evaluation of the can-
didates, 98 were excluded. The most common reasons
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iso- or hyperoncotic colloid, a drug or procedure con-
trol, and an investigational design other than a parallel-
group RCT. Eleven RCTs with a total of 1,220 patients
fulfilled all eligibility criteria and were included in the
meta-analysis [17-27]. All trials had been published.
Three of the 11 included trials were reported in the
1980 s and four each in the 1990 s and 2000 s (Table
1). Two trials were blinded and two were not, whereas
the use of blinding was unspecified for the remaining
seven trials. Allocation concealment was adequate in
five trials and unspecified in six. The indication for
volume expansion with colloid was treatment of ascites
as an adjunct to paracentesis in three trials and to diure-
tics in one, surgery in three, and sepsis and spontaneous
bacterial peritonitis in two each. One trial encompassed
separate protocols for acute treatment of ascites in the
hospital and subsequent long-term outpatient mainte-
nance therapy [22]. Only the results from the acute
treatment protocol were used in the meta-analysis. The
median number of patients per trial was 72, and the
interquartile range (IQR) was 32 to 116. More than 100
patients were evaluated in four trials, but only one trial
involved over 200 patients. With 537 patients, that trial
[25] was by far the largest included in the meta-analysis.
Mean ages of patients in the trials were comparatively
homogeneous. Whereas age averaged 49.1 years in one
trial, the mean values in the other 10 trials fell within
the relatively narrow range of 55.7 to 64.7 years. The
median percentage of male patients in the included
trials was 60% (IQR 60% to 65%). Seven trials evaluated
hyperoncotic 20% to 25% albumin, and four trials evalu-
ated hyperoncotic 10% HES. Control treatments were
no colloid in seven trials, crystalloid in three, and hypo-
oncotic colloid in one.
Acute kidney injury
The AKI diagnosis criteria adopted in four trials
included an increase of 50% or more in serum creatinine
or blood urea nitrogen (Table 1). The need for RRT was
the criterion in three trials, whereas other or unspecified
criteria were applied in two trials each. Across all 11
studies, 199 of 1,220 patients (16%) developed AKI (Fig-
ure 2). As shown in Figure 2, hyperoncotic albumin
decreased the odds of AKI by 76% (OR 0.24, CI 0.12 to
0.48; P < 0.0001). Among the seven trials evaluating
hyperoncotic albumin, there was no evidence of either
heterogeneity (P = 0.81; I
2 =0 % )o rp u b l i c a t i o n( P =
0.74) bias with respect to the AKI endpoint. Hyperonco-
tic HES showed the opposite effect (Figure 2), increasing
the odds of AKI by 92% (OR 1.92, CI 1.31 to 2.81; P =
0.0008). Neither heterogeneity (P = 0.89; I
2 =0 % )n o r
publication (P = 0.55) bias was detectable in the AKI
data from the four trials of hyperoncotic HES.
109 Candidate RCTs
Identified and Screened
26 with Iso- or Hyperoncotic or 
Non-Fluid Control Excluded
6 with Non-Hypovolemia 
Colloid Indication Excluded
29 with Nonhyperoncotic Test 
Colloid Excluded
23 Excluded Because Not 
Parallel-Group RCTs
10 Excluded Because
No AKI Data
11 RCTs
Included
4 Excluded Because Patients 
Not Randomized to Colloid
Figure 1 Randomized controlled trial (RCT) selection process. AKI, acute kidney injury.
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Among all 11 included trials, 283 of 1,220 patients
(23%) died. At least one death occurred in 10 of the 11
included trials, allowing those 10 trials (with a total of
1,185 patients) to be included in a meta-analysis evalu-
ating the OR for mortality (Figure 3). The only trial
with no deaths assessed hyperoncotic albumin in the
treatment of ascites [20]. Hyperoncotic albumin
reduced the odds of mortality by 48% (OR 0.52, CI
0.28 to 0.95; P = 0.035; Figure 3). No significant het-
erogeneity (P = 0.81; I
2 = 0%) or publication (P =0 . 1 2 )
bias was present regarding mortality in the six trials of
hyperoncotic albumin with at least one death. Conver-
sely, hyperoncotic HES raised the odds of mortality by
41% (OR 1.41, CI 1.01 to 1.96; P = 0.043). The mortal-
ity data in the hyperoncotic HES trials did not display
either heterogeneity (P =0 . 8 9 ;I
2 = 0%) or publication
(P = 0.14) bias.
Discussion
This meta-analysis of RCTs did not support the hypoth-
esis that hyperoncotic colloids per se are injurious to the
kidney. It appeared that, within physiologic ranges, the
specific properties of the colloid molecule rather than
concentration are the major determinants of renal
effects. According to our results, administration of
hyperoncotic albumin was associated with reduced risk
of AKI as well as with improved survival. By contrast,
HES displayed nephrotoxicity and worsened survival.
Certain limitations of this meta-analysis should be
noted. Criteria for diagnosing AKI were not standar-
dized. Other than one surgery trial, all six other
included trials of hyperoncotic albumin involved cirrho-
tic patients, whereas those evaluating hyperoncotic HES
all concerned surgery or sepsis. Thus, the clinical set-
tings for evaluation of the two hyperoncotic colloids
were largely non-overlapping.
Table 1 Included randomized trials
Trial Indication Mean
age,
years
Treatment AKI criteria
Zetterström
and
Hedstrand
[17], 1981
Elective major abdominal surgery 58.5 Postoperative crystalloid with
versus without 20% albumin
At least 70% SCr and urea increase
Ginès et al.
[18], 1988
Treatment of ascites in
hospitalized cirrhotic patients
57.0 Paracentesis with versus without
20% albumin
At least 50% SCr or BUN increase to greater than
1.5 or 30 mg/dL, respectively
London et al.
[19], 1989
CPB surgery 63.5 10% pentastarch versus 5%
albumin for first 24 hours
postoperatively
Emergency dialysis necessitated by acute renal
failure
García-
Compeán et
al. [20], 1993
Hospital treatment of tense ascites
causing respiratory dysfunction in
cirrhotic patients
55.7 Total therapeutic paracentesis with
versus without 25% albumin
Greater than 50% SCr or BUN increase to greater
than 1.5 mg/dL or greater than 30 mg/dL,
respectively
Dehne et al.
[21], 1997
Hypovolemia in surgical ICU
patients
49.1 Normocaloric parenteral nutrition
with versus without 12 mL/kg per
day HES 200/0.5
Acute renal failure
Gentilini et
al. [22], 1999
Hospital treatment of ascites in
cirrhotic patients unresponsive to
bed rest and low-sodium diet
62.1 Diuretics with versus without 50
mL 25% albumin daily
Acute renal failure
Sort et al.
[23], 1999
Spontaneous bacterial peritonitis 61.0 Intravenous cefotaxime with versus
without 1.5 g/kg 20% albumin on
day 1 plus 1.0 g/kg on day 3
Greater than 50% SCr or BUN increase and, in
patients without pre-existing renal failure, greater
than 1.5 mg/dL SCr or greater than 30 mg/dL BUN
Sola-Vera et
al. [24], 2003
Prevention of paracentesis-
induced circulatory dysfunction in
cirrhotic patients with ascites
61.4 20% albumin versus saline starting
3 hours after paracentesis
Greater than 100% SCr increase to greater than 2
mg/dL
Brunkhorst et
al. [25], 2008
Severe sepsis or septic shock 64.7 10% pentastarch versus Ringer’s
lactate
Need for renal replacement therapy
a
McIntyre et
al. [26], 2008
Early septic shock 63.3 10% pentastarch versus normal
saline
Requirement for dialysis during hospitalization
Chen et al.
[27], 2009
Spontaneous bacterial peritonitis 56.5 Cephalosporins with versus
without 50 mL 20% albumin on
days 1 to 3
Greater than 50% SCr increase and, in patients
without pre-existing renal failure, greater than 1.5
mg/dL SCr
aNeed based on the presence of acute renal failure or another indication such as volume overload or hyperkalemia. Acute renal failure, defined as a doubling of
the baseline serum creatinine (SCr) level or the need for renal replacement therapy, was evaluated as an additional separate endpoint in this trial. For the meta-
analysis, only the data for renal replacement therapy were used. AKI, acute kidney injury; BUN, blood urea nitrogen; CPB, cardiopulmonary bypass; HES,
hydroxyethyl starch; ICU, intensive care unit.
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tic albumin involved cirrhotic patients. In all six of
those trials, the observed reduction in the AKI inci-
dence was less than in the seventh trial, which evaluated
major abdominal surgery patients [17]. Extravascular
fluid accumulation is a common complication of cirrho-
sis, which might be precipitated or exacerbated by
hypo-oncotic fluid, and in five of the six included trials
of cirrhotic patients, the selected control regimen con-
sisted of no volume expander. The possibility could be
entertained that volume expansion with a control fluid
might have produced the same results as did hyperon-
cotic albumin in those trials. In one included trial [24],
however, cirrhotic patients with ascites did receive sal-
ine as the control fluid. That group developed paracent-
esis-induced circulatory dysfunction with a frequency
that was significantly higher (33.3%) than that of the
patients allocated to hyperoncotic albumin (11.4%).
Additionally, a randomized trial not included in this
meta-analysis compared hyperoncotic 20% albumin with
iso-oncotic 6% HES 200/0.5 in cirrhotic patients with
spontaneous bacterial peritonitis [28]. Although the trial
was not powered to assess AKI, the incidence of AKI
was nevertheless lower in the hyperoncotic albumin
group (OR 0.29, CI 0.03 to 3.12), and significant
improvement in circulatory function was demonstrated
in that group but not among the patients assigned to
iso-oncotic HES.
The present meta-analysis is the first to investigate
AKI specifically after infusion of hyperoncotic 10% HES.
Prior systematic reviews and meta-analyses have not dif-
ferentiated between iso-oncotic and hyperoncotic HES
solutions [1-3,29]. Even in the CRYCO analysis, the
designated hyperoncotic HES group did not actually
receive hyperoncotic solutions exclusively [5]. Iso-onco-
tic 6% HES 130/0.4, for example, was among the solu-
tions assigned to the CRYCO hyperoncotic HES group.
In three of the four included trials evaluating hyperon-
cotic HES, AKI was more frequent in the hyperoncotic
HES group than the control group, and in all four of
those trials, mortality was higher in hyperoncotic HES
recipients. Nevertheless, the preponderance of the statis-
tical power was derived from as i n g l el a r g et r i a l[ 2 5 ] ,
and it should be recognized that the conclusions of the
meta-analysis regarding hyperoncotic HES rest primarily
on that trial. If that trial were to be excluded, the point
estimates of the pooled ORs for AKI (1.53) and mortal-
ity (1.91) would be comparable to those without the
Study name Odds ratio and CI Odds Lower Upper
ratio limit limit
Zetterström, Hedstrand 1981 0,062 0,003 1,24
Ginès et al. 1988 0,070 0,004 1,27
García-Compeán et al. 1993 0,50 0,041 6,08
Hyperoncotic albumin
Hyperoncotic
colloid, AKI/N
Control,
AKI/N
0/15 5/15
0/52 6/53
1/17 2/18
0,24 0,12 0,48
Hyperoncotic HES
London et al. 1989 0.88 0,053 14,5
Dehne et al. 1997 1,33 0,25 7,01
Pooled 10/262 42/262
1/50 1/44
4/10 5/15
Gentilini et al. 1999 0,19 0,009 4,12
Sort et al. 1999 0,21 0,078 0,57
Sola-Vera et al. 2003 0,61 0,096 3,89
0/63 2/63
6/63 21/63
2/37 3/35
Chen et al. 2009 0,29 0,026 3,12 1/15 3/15
Brunkhorst et al. 2008 1,97 1,32 2,94
McIntyre et al. 2008 3,00 0,28 31,6
81/262 51/275
3/21 1/19
1,92 1,31 2,81
Favors
control
Favors
hyperoncotic colloid
Pooled 89/343 58/353
Figure 2 Meta-analysis of acute kidney injury (AKI) after hyperoncotic colloid administration. Data points are scaled in proportion to
meta-analytic weight. Error bars indicate confidence interval (CI). HES, hydroxyethyl starch; N, total number of patients.
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effects would no longer be statistically significant.
While this meta-analysis has shown increased risk of
AKI because of hyperoncotic HES, randomized trials
have demonstrated similar deleterious renal effects in
patients receiving iso-oncotic HES [15,16]. Furthermore,
in the CRYCO analysis, the incidence of AKI among
recipients of iso-oncotic 6% HES 130/0.4 was similar to
that of recipients of other evaluated HES solutions.
The present finding of renal protection attributable to
hyperoncotic albumin in randomized trials is in contrast
to the report of increased AKI in the hyperoncotic albu-
min group from the CRYCO analysis. Several factors
may limit the reliability and generalizability of the
CRYCO results with respect to hyperoncotic albumin,
namely use of hyperoncotic albumin in a small minority
of the most severely ill patients, concomitant infusion of
other colloids, absence of a demonstrated dose-response
relationship, and exclusion of cirrhotic patients.
No evidence of adverse renal effects was uncovered in
a multicenter study of 600 patients receiving 25% albu-
min [14]. In that observational study, which was specifi-
cally designed to evaluate safety, normothermic
hypoproteinemic patients at 14 US hospitals received
multiple infusions of 80 to 100 mL of 25% albumin over
a maximum period of 570 days. Forty-four patients
underwent more than 10 infusions each, and the cumu-
lative dose administered to five patients exceeded 800 g.
The patients were closely monitored for adverse events,
including pyrogenic reactions, anaphylactoid and cardio-
vascular symptoms, and pulmonary edema. Post-mortem
examination of 16 patients who had received 25% albu-
min doses up to 813 g each showed no evidence of
abnormal albumin storage or other renal abnormalities
that could not be explained by the disease of which the
patients died.
On the basis of the CRYCO findings, recently issued
clinical guidelines recommended the avoidance of
hyperoncotic dextran, HES, and albumin solutions
because of the risk for renal dysfunction [30]. In light of
this meta-analysis and the limitations of the CRYCO
study, such a blanket recommendation would appear to
be unwarranted. A more differentiated approach to the
use of these solutions is needed, as recommended in a
recent publication [4].
Albumin-mediated renoprotection may be explained
by several mechanisms, including maintaining renal per-
fusion [6,31,32], promoting proximal tubular integrity
and function [22,33-38], binding of endogenous toxins
and nephrotoxic drugs [39-42], and preventing oxidative
Study name Odds ratio and CI Odds Lower Upper
ratio limit limit
Zetterström, Hedstrand 1981
Ginès et al. 1988
Hyperoncotic albumin
Hyperoncotic
colloid, Dead/N
Control,
Dead/N
0/15 1/15
2/52 2/53
Hyperoncotic HES
London et al. 1989
Dehne et al. 1997
Pooled 22/245 36/244
2/50 1/44
4/10 3/15
Gentilini et al. 1999
Sort et al. 1999
Sola-Vera et al. 2003
1/63 0/63
14/63 26/63
1/37 1/35
Chen et al. 2009 4/15 6/15
Brunkhorst et al. 2008
McIntyre et al. 2008
107/262 93/275
9/21 6/19
0,31 0,012 8,28
1,02 0,14 7,52
0,52 0,28 0,95
1.79 0,16 20,5
2,67 0,45 16,0
3,05 0,12 76,3
0,41 0,19 0,88
0,94 0,057 15,7
0,55 0,12 2,55
1,35 0,95 1,92
1,62 0,44 5,95
1,41 1,01 1,96
Favors
control
Favors
hyperoncotic colloid
Pooled 122/343 103/353
Figure 3 Meta-analysis of mortality after hyperoncotic colloid administration.G r a p h i cc o n v e n t i o n sa r et h es a m ea si nF i g u r e2 .C I ,
confidence interval; HES, hydroxyethyl starch; N, total number of patients.
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sphatidic acid [34,36,43,44]. The important renoprotec-
tive role of serum albumin was underscored by a recent
meta-analysis showing hypoalbuminemia to be a potent
independent risk factor both for AKI and for death fol-
lowing the development of AKI [45].
Many medications have been associated with toxic
effects on the kidney [46]. Because the kidney receives a
quarter of resting cardiac output, glomerular, tubular,
and renal interstitial cells can be exposed to substantial
concentrations of medications and their metabolites,
which can induce changes in kidney structure and func-
tion. On the other hand, several mechanisms of HES-
induced AKI are reported. HES is degraded and its
degradation products are reabsorbed mainly in the prox-
imal tubule. Intracellular accumulation resulting in
vacuolization of the proximal tubule may result in func-
tional impairment. Post-mortem examination of 12
patients who received repeated HES 200/0.5 infusions
and died after protracted RRT because of ARF showed
that the kidney contained the highest tissue concentra-
tion of HES compared with any of the other six major
organs evaluated [47]. Degradation products of HES are
cleared primarily via the kidney. Some of these break-
down products are excreted in the urine, but others can
be taken up by the cells of the proximal tubule through
pinocytosis. The pinocytotic vacuoles subsequently fuse
with each other and lysosomes to form larger vacuoles,
which can displace other cellular components. HES can
accumulate through storage in these oversized lyso-
somes. There have been no studies published thus far
on the type of HES metabolites taken up in the vacuoles
and the ability of lysosomal enzymes to degrade them.
Vacuolization and swelling of the renal proximal tubular
cells are often harbingers of AKI [48].
The histopathologic pattern of acute tubular injury
typical of HES accumulation in the kidney is osmotic
nephrosis. This phenomenon was first described in 1940
when patients with increased intracranial pressure were
treated with intravenous sucrose solutions [48]. Dextran,
another colloid composed of glucose units, has also
been associated with osmotic nephrosis [1], as have mal-
tose and mannitol [48]. Numerous case reports have
documented osmotic nephrosis in patients developing
AKI after HES exposure [49-52]. In a randomized trial,
HES increased the need for RRT after kidney transplan-
tation, and all biopsied patients receiving HES showed
osmotic nephrosis, but none in the control group did
[16]. Hydroxyethylation of constituent glucose molecules
in the synthesis of HES is specifically intended to retard
degradation and prolong action. Osmotic nephrosis
resulting from HES exposure can be extremely long-last-
ing, if not permanent. During long-term follow-up after
orthotopic liver transplantation, osmotic nephrosis
attributable to HES persisted up to 10 years in 61% of
patients [53].
Decreasing levels of renoprotective albumin might be
an additional mechanism underlying the nephrotoxicity
of HES, which has been shown to cause iatrogenic
hypoalbuminemia [54-59]. Inflammatory processes may
also contribute to HES-mediated AKI [60]. Further
research is needed on pathophysiologic mechanisms as
well as on the metabolic fate of HES in the kidney.
Only relatively recently has attention been focused on
the possibility that hyperoncotic fluids per se might be
injurious to the kidney. Accordingly, the hypotheses
tested in the trials of this meta-analysis were not formu-
lated specifically in terms of evaluating a hyperoncotic
colloid. Nevertheless, in those trials, patients were ran-
domly allocated to a hyperoncotic colloid or control
regimen, and the trials therefore do provide relevant evi-
dence of the renal effects of hyperoncotic colloids. It has
recently become increasingly common to discuss ‘hyper-
oncotic acute renal failure’. This meta-analysis raises
doubt that such a concept can satisfactorily account for
AKI in patients receiving colloids.
Conclusions
Currently available randomized trial evidence suggests
that hyperoncotic albumin solutions may reduce the
incidence of AKI and death. The opposite effects appear
to be exerted by hyperoncotic HES.
Key messages
￿ It has been hypothesized that hyperoncotic colloid
solutions may damage the kidney. A meta-analysis of
randomized controlled trials was performed to test
this hypothesis.
￿ Hyperoncotic albumin decreased the odds of acute
kidney injury by 76% and of death by 48%.
￿ Hyperoncotic hydroxyethyl starch increased the odds
of acute kidney injury by 92% and of death by 41%.
￿ Hyperoncotic colloids per se do not appear to be
harmful to the kidney.
￿ Renal effects may be specific to the particular col-
loid molecule.
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